CytoMed Therapeutics Ltd
GDTC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GDTC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GDTC
CytoMed Therapeutics Ltd (GDTC) is a clinical-stage biopharmaceutical company focused on developing novel cell-based immunotherapies for cancer, with a lead product candidate CTM-N2D and a pipeline including iPSC-gdNKT, CTM-GDT, CTM-MSC, and CTM-NK. The company has limited cash resources and a history of losses, and its ability to continue as a going concern depends on securing additional financing.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
CytoMed Therapeutics Ltd (GDTC) is a clinical-stage biopharmaceutical company focused on developing novel cell-based immunotherapies for cancer, with a lead product candidate CTM-N2D and a pipeline including iPSC-gdNKT, CTM-GDT, CTM-MSC, and CTM-NK. The company has limited cash resources and a history of losses, and its ability to continue as a going concern depends on securing additional financing.
- Lead product candidate is CTM-N2D, with other pipeline candidates including iPSC-gdNKT, CTM-GDT, CTM-MSC, and CTM-NK [sec · filed 2026-03-31].
- Cash and equivalents were $1.6M as of 2025-12-31, with total revenue of $0.3M and a net loss of -$3.1M for the same period [sec].
- Accumulated losses were S$14.85 million as of the most recent filing [sec · filed 2026-03-31].
- The company has 42 full-time employees and expects to need to expand its workforce to support operations and clinical trials [sec · filed 2026-03-31].
- There is substantial doubt about the company's ability to continue as a going concern, and it will require additional capital to fund operations [sec · filed 2025-04-28].
What works
- The company has a pipeline of multiple product candidates (CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC, CTM-NK) targeting different cancer indications, providing potential diversification [sec · filed 2026-03-31].
- CTM-N2D is based on a core proprietary technology that also underlies CTM-GDT, suggesting a shared platform that could be leveraged across candidates [sec · filed 2026-03-31].
- The company has prior experience in cell therapy development, as some employees have prior exposure to the field [sec · filed 2026-03-31].
What to weigh
- The company has a very limited cash position ($1.6M as of 2025-12-31) and a history of net losses, with accumulated losses of S$14.85 million [sec · filed 2026-03-31].
- There is substantial doubt about the company's ability to continue as a going concern, and it may need to raise additional capital, which could be dilutive or require relinquishing rights to product candidates [sec · filed 2025-04-28].
- The company's business is highly dependent on the success of its lead candidate CTM-N2D; any problems with CTM-N2D could significantly hinder the entire pipeline [sec · filed 2026-03-31].
- The company faces risks from potential delays in clinical trials, regulatory approvals, and market acceptance, and may not be able to generate product revenues [sec · filed 2026-03-31].
From the filings
Quoted directly from source documents.
The company's lead product candidate is CTM-N2D, and its pipeline includes multiple other candidates.
“CTM-N2D is our lead product candidate and CTM-GDT is based on the same core proprietary technology”
SEC filings · March 31, 2026
The company has accumulated significant losses and expects to continue incurring losses.
“accumulated losses of S$14.85 million and S$18.83 million, respectively. Given that we will continue to invest most of our resources in developing our product candidates, we expect to continue to incur increasing losses for the foreseeable future.”
SEC filings · March 31, 2026
There is substantial doubt about the company's ability to continue as a going concern.
“there remains substantial doubt about our ability to continue as a going concern”
SEC filings · April 28, 2025
The company has 42 full-time employees and needs to expand.
“As of the date of this annual report, we have forty-two (42) full-time employees.”
SEC filings · March 31, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; may need to liquidate assets [sec · filed 2025-04-28].
- Dependence on lead candidate — Problems with CTM-N2D could hinder entire pipeline, including CTM-GDT [sec · filed 2026-03-31].
- Limited cash runway — Cash of $1.6M as of 2025-12-31; may require additional financing to fund operations [sec].
- Regulatory and clinical delays — Delays in obtaining regulatory approvals or completing trials could harm business [sec · filed 2026-03-31].
What to watch
- Ability to secure additional financing to fund operations and clinical development [sec · filed 2026-03-31].
- Progress of CTM-N2D clinical trials, particularly any safety or efficacy data [sec · filed 2026-03-31].
- Regulatory developments for CTM-N2D and other pipeline candidates [sec · filed 2026-03-31].
- Expansion of workforce and operational capabilities to support growth [sec · filed 2026-03-31].
Sources: SEC filings · Generated August 10, 2026 · How we verify sources →
Run CytoMed Therapeutics Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CytoMed Therapeutics Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.1 months
D/E 0.17
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$10K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 10,136 | $10K |
| osaic holdings, inc. | 21 | $21 |
Short Interest
as of Apr 21, 2026- % of float
- 2.4%
- Days to cover
- 8.2
- Shares short
- 82,681
- Daily short volume (Aug 28, 2026)
- 29.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GDTC short interestFrequently asked questions
What is the AI investment thesis for CytoMed Therapeutics Ltd?
CytoMed Therapeutics Ltd (GDTC) is a clinical-stage biopharmaceutical company focused on developing novel cell-based immunotherapies for cancer, with a lead product candidate CTM-N2D and a pipeline including iPSC-gdNKT, CTM-GDT, CTM-MSC, and CTM-NK. The company has limited cash resources and a history of losses, and its ability to continue as a going concern depends on securing additional financing.
Where is CytoMed Therapeutics Ltd headquartered?
CytoMed Therapeutics Ltd (GDTC) is headquartered in Singapore, Singapore.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.